Εμφάνιση απλής εγγραφής

dc.creatorFountzilas, G.en
dc.creatorKarkavelas, G.en
dc.creatorKalogera-Fountzila, A.en
dc.creatorKarina, M.en
dc.creatorIgnatiadis, M.en
dc.creatorKoukoulis, G.en
dc.creatorPlataniotis, G.en
dc.creatorMisailidou, D.en
dc.creatorBobos, M.en
dc.creatorPectasides, D.en
dc.creatorRazis, E.en
dc.creatorKaravelis, A.en
dc.creatorSelviaridis, P.en
dc.date.accessioned2015-11-23T10:26:44Z
dc.date.available2015-11-23T10:26:44Z
dc.date.issued2006
dc.identifier.issn0250-7005
dc.identifier.urihttp://hdl.handle.net/11615/27553
dc.description.abstractBackground: Clinical studies have shown that temozolomide (TMZ) and irinotecan demonstrate activity in high grade astrocytic tumors (HGAT). However, the optimal schedule of administration is unknown. Patients and Methods: In the present study, a total of 45 HGAT patients, 38 with glioblastoma multiforme (GBM) and 7 with anaplastic astrocytoma (AA), were treated with TMZ, 150 mg/m(2) on days 1-5, followed by irinotecan, 150 mg/m(2) on days 6 and 17, every 4 weeks,for 6 cycles or until the occurrence of unacceptable toxicity or disease progression. Radiation therapy (60 Gy) was initiated on the first day of treatment. Results: Twenty-two patients completed six cycles of treatment. Most frequently recorded side-effects included neutropenia (37%), nausea/vomiting (66%), diarrhea (31%) and infection (44%). Five episodes of vaso-occlusive disease, all of them fatal, were observed. After a median follow-up of 49.8 months, median progression-free survival for patients with GBM was 7.7 months, while median overall survival was 12.8 months. There were six long-term survivors, three of them with GBM. Two out of the five biomarkers studied, epidermal growth factor receptor (EGFR) and vascular endothelial growth factor-C (VEGF-C), were found to be overexpressed in 74% of the tumors, however they had no predictive value for progression-free or overall survival. Conclusion: The combination of TMZ and irinotecan, as administered in this study, was accompanied by high rates of toxicity, especially myelotoxicity and infection. Further development of this regimen in the treatment of HGAT is not recommended.en
dc.source.uri<Go to ISI>://WOS:000243083600008
dc.subjectbrain tumorsen
dc.subjecttemozolomideen
dc.subjectcamptothecinsen
dc.subjectchemotherapyen
dc.subjectglioblastomasen
dc.subjectmultiformeen
dc.subjectgliomasen
dc.subjectGROWTH-FACTOR RECEPTORen
dc.subjectPRIMARY BRAIN-TUMORSen
dc.subjectGLIOBLASTOMA-MULTIFORMEen
dc.subjectIMMUNOHISTOCHEMICAL ANALYSISen
dc.subjectVENOUS THROMBOEMBOLISMen
dc.subjectMALIGNANT GLIOMASen
dc.subjectSIGNALING PATHWAYen
dc.subjectIN-VIVOen
dc.subjectEXPRESSIONen
dc.subjectADENOCARCINOMASen
dc.subjectOncologyen
dc.titlePost-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluationen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής